← Leaderboards
Scott Kurtzman
University Of Connecticut Sch Of Med/Dnt
$205,028
Attributed
$205,028
Total exposure
38
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $47.7K · FY2005–08$50K$37.5K$25K$12.5K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$205,028 · 38
By mechanism
M01$205,028 · 38
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchBreast NeoplasmsHuman Therapy EvaluationTamoxifenCancer PreventionNeoplasm /Cancer ChemotherapyFemaleClinical TrialsCyclophosphamideWomen'S HealthInstitutionSourceResearch PersonnelCombination ChemotherapyDoxorubicinComputer Retrieval Of Information On Scientific Projects DatabaseGrantFundingResourcesUnited States National Institutes Of HealthNational Surgical Adjuvant Breast And Bowel ProjectNeoplasm /Cancer SurgeryPaclitaxel
Grant awards (68)
CLINICAL TRIAL: NSABP P-2: STAR$11,871
M01 · FY2008 · RR · contact PI
NSABP P-2: STAR$15,998
M01 · FY2007 · RR · contact PI
NSABP B-35$1,882
M01 · FY2007 · RR · contact PI
NSABP B-38$1,568
M01 · FY2007 · RR · contact PI
NSABP B-31$784
M01 · FY2007 · RR · contact PI
NSABP B-27$471
M01 · FY2007 · RR · contact PI
NSABP B-28$471
M01 · FY2007 · RR · contact PI
NSABP- B33$314
M01 · FY2007 · RR · contact PI
NSABP-B34$314
M01 · FY2007 · RR · contact PI
NSABP CO-7$314
M01 · FY2007 · RR · contact PI
NSABP TREATMENT B21$157
M01 · FY2007 · RR · contact PI
NSABP P-2: STAR$31,219
M01 · FY2006 · RR · contact PI
NSABP P-1 TRIAL$1,156
M01 · FY2006 · RR · contact PI
NSABP B-31$1,156
M01 · FY2006 · RR · contact PI
NSABP B-38$867
M01 · FY2006 · RR · contact PI
NSABP B-27$578
M01 · FY2006 · RR · contact PI
NSABP B-28$578
M01 · FY2006 · RR · contact PI
NSABP-B34$578
M01 · FY2006 · RR · contact PI
NSABP- B33$289
M01 · FY2006 · RR · contact PI
NSABP CO-7$289
M01 · FY2006 · RR · contact PI
NSABP PROTOCOL P-2: STAR$40,517
M01 · FY2005 · RR
ACSOG-Z0010$2,805
M01 · FY2005 · RR
TRIAL TO DETERMINE THE WORTH OF TAMOXIFEN FOR PREVENTING BREAST CANCER$935
M01 · FY2005 · RR
NSABP-B34$935
M01 · FY2005 · RR
NSABP B-27$624
M01 · FY2005 · RR
NSABP B23 AC VS CMF$624
M01 · FY2005 · RR
NSABP B-35$624
M01 · FY2005 · RR
NSABP B-31$311
M01 · FY2005 · RR
NSABP CO-7$311
M01 · FY2005 · RR
NSABP Protocol P-2: STAR$34,577
M01 · FY2004 · RR
HEDA$2,675
M01 · FY2004 · RR
ACSOG-Z0010$1,146
M01 · FY2004 · RR
Worth of Tamoxifen for Preventing Breast Cancer$764
M01 · FY2004 · RR
NSABP-B34$382
M01 · FY2004 · RR
NSABP TREATMENT TRIALS$0
M01 · FY2002 · RR
TRIAL TO DETERMINE THE WORTH OF TAMOXIFEN FOR PREVENTING BREAST CANCER$0
M01 · FY2002 · RR
NSABP TREATMENT TRIALS$4,361
M01 · FY2001 · RR
TRIAL TO DETERMINE THE WORTH OF TAMOXIFEN FOR PREVENTING BREAST CANCER$4,361
M01 · FY2001 · RR
TRIAL TO DETERMINE THE WORTH OF TAMOXIFEN FOR PREVENTING BREAST CANCER$0
M01 · FY2001 · RR
NSABP TREATMENT TRIALS$0
M01 · FY2001 · RR
NSABP TREATMENT TRIALS$0
M01 · FY2001 · RR
TRIAL TO DETERMINE THE WORTH OF TAMOXIFEN FOR PREVENTING BREAST CANCER$0
M01 · FY2001 · RR
TRIAL TO DETERMINE THE WORTH OF TAMOXIFEN FOR PREVENTING BREAST CANCER$19,111
M01 · FY2000 · RR
NSABP TREATMENT TRIALS$19,111
M01 · FY2000 · RR
NSABP B23--AC versus CMF in node negative breast cancer$0
M01 · FY2000 · RR
NSABP B-27--Preoperative doxorubicin/cyclophosphamide/docetaxel in breast cancer$0
M01 · FY2000 · RR
NSABP B-27--Preoperative doxorubicin/cyclophosphamide/docetaxel in breast cancer$0
M01 · FY2000 · RR
NSABP B-27--Preoperative doxorubicin/cyclophosphamide/docetaxel in breast cancer$0
M01 · FY2000 · RR
NSABP B1-65--Menstrual cycle &surgical treatment of breast cancer$0
M01 · FY2000 · RR
NSABP B1-65--Menstrual cycle &surgical treatment of breast cancer$0
M01 · FY2000 · RR
NSABP B1-65--Menstrual cycle &surgical treatment of breast cancer$0
M01 · FY2000 · RR
NSABP B27.1--Tumor biomarkers in breast cancer$0
M01 · FY2000 · RR
NSABP B27.1--Tumor biomarkers in breast cancer$0
M01 · FY2000 · RR
NSABP B27.1--Tumor biomarkers in breast cancer$0
M01 · FY2000 · RR
NSABP TREATMENT TRIALS$0
M01 · FY2000 · RR
NSABP TREATMENT TRIALS$0
M01 · FY2000 · RR
TRIAL TO DETERMINE THE WORTH OF TAMOXIFEN FOR PREVENTING BREAST CANCER$0
M01 · FY2000 · RR
TRIAL TO DETERMINE THE WORTH OF TAMOXIFEN FOR PREVENTING BREAST CANCER$0
M01 · FY2000 · RR
NSABP P2--Tamoxifen &raloxifene for prevention of breast cancer$0
M01 · FY2000 · RR
NSABP P2--Tamoxifen &raloxifene for prevention of breast cancer$0
M01 · FY2000 · RR
NSABP P2--Tamoxifen &raloxifene for prevention of breast cancer$0
M01 · FY2000 · RR
NSABP B23--Adriamycin/cyclophosamide/methotrexate/fluorouracil in breast cancer$0
M01 · FY2000 · RR
NSABP B23--Adriamycin/cyclophosamide/methotrexate/fluorouracil in breast cancer$0
M01 · FY2000 · RR
NSABP B28--Taxol/adriamycin/cyclophosphamide in breast cancer$0
M01 · FY2000 · RR
NSABP B28--Taxol/adriamycin/cyclophosphamide in breast cancer$0
M01 · FY2000 · RR
NSABP B28--Taxol/adriamycin/cyclophosphamide in breast cancer$0
M01 · FY2000 · RR
NSABP B23--AC versus CMF in node negative breast cancer$0
M01 · FY2000 · RR
NSABP B23--AC versus CMF in node negative breast cancer$0
M01 · FY2000 · RR